A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

From the Capital of France to the Capital of New York — a cutting-edge biotech firm that uses AI to research cancer ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

The Fremont company sold extra shares at the top of its proposed range, and the stock jumped more than 30% in initial trading ...

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point ...

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next ...

Windlas Biotech approved a Rs 47 crore share buyback at Rs 1,000 per share via the tender route, with April 24 set as the ...